Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 3:31 PM ET

Pharmaceuticals

Company Overview of Hydra Biosciences, Inc.

Company Overview

Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.

45 Moulton Street

Cambridge, MA 02138

United States

Founded in 2001

Phone:

617-494-5230

Fax:

617-494-5245

Key Executives for Hydra Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 55
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Interim Chief Financial Officer
Compensation as of Fiscal Year 2014.

Hydra Biosciences, Inc. Key Developments

Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100

Hydra Biosciences announced that Health Canada approved the company’s Clinical Trial Application (CTA) to begin a Phase 1 study of HX-100. This study will provide the safety data necessary for Phase 2 studies in painful diabetic neuropathy (PDN) and allergic asthma that are expected to begin later this year. TRP channels are membrane-bound proteins that play a role in controlling cellular calcium levels and excitability in response to a variety of stimuli. The 28 members of the TRP family differ from better-known ion channels in that they are not primarily voltage gated and have significant sequence diversity, providing the opportunity to develop truly selective modulators. In addition to their well-documented role in pain and pulmonary disorders, TRPs have been linked to CNS, renal and dermatological diseases. TRPA1 is a member of the TRP family, activated by reactive chemicals, products of aberrant glucose metabolism, tissue injury, and inflammation. Environmental irritants that lead to channel activity include common asthma triggers such as cigarette smoke, ozone and chlorine. HX-100 is a highly selective, potent inhibitor of TRPA1. Pre-clinical data demonstrate promising safety and efficacy with several potential advantages over currently available treatments for chronic pain and asthma. HX-100 can be taken orally, and it is expected to have robust efficacy without abuse liabilities, given the limited expression of TRPA1 in the brain. This Phase 1 trial of HX-100 follows a standard single ascending dose and multiple ascending dose design with approximately 90 healthy volunteers. The company expects to initiate separate Phase 2 studies in painful diabetic neuropathy and allergic asthma in late 2015 with results from these trials expected before the end of 2016.

Hydra Biosciences, Inc. and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders

Hydra Biosciences, Inc. and Boehringer Ingelheim announced that they have entered into a worldwide research collaboration and license agreement to identify small-molecule TRP inhibitors, with a primary focus on the treatment of renal diseases and disorders. Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an undisclosed upfront payment, additional research funding, and the company is eligible to receive milestone payments and tiered royalty payments on future product sales.

Hydra Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM

Hydra Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Vemas Herb & Health United States
BML Pharmaceuticals, Inc. United States
Dual Therapeutics, LLC United States
Enturia, Inc. United States
D.P. Marketing, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 17, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hydra Biosciences, Inc., please visit www.hydrabiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.